VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY DATA OF NOVEL B7-H3 ANTIBODY-DRUG CONJUGATE SYS6043 PRESENTED IN AN ORAL SESSION AT THE 2026 ASCO ANNUAL MEETING

Contact Us

Products

• Core Product
• API
• Formulation
• Quality Assurance

Science

• R&D
• Solutions

About Us

• Who are we
• Our history
• Main production base
• Governance and Leadership